Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
2697
LUME-Lung 1 Infographic thumb
 
Rating:00
view image larger
Related links:
LUX Lung 1 Clinical Trial Infographic thumb
LUX Lung 1 Clinical Trial Infographic
Read more >

LUME-Lung 1 infographic

01.05.2011

The LUME-Lung Phase III programme for BIBF 1120*, comprises two multinational trials. These placebo-controlled studies are investigating the safety and efficacy of BIBF 1120* in NSCLC patients after first line chemotherapy treatment. In the LUME-Lung 1 trial, which includes patients with all histologies, BIBF 1120* is administered in combination with standard chemotherapy agent docetaxel. The last patient was recruited to LUME-Lung 1 in early February 2011. In the LUME-Lung 2 trial, which includes only patients with non-squamous cell carcinomas, BIBF 1120* is administered in combination with pemetrexed. Approximately 2,600 patients will be enrolled, making this one of the largest Phase III study programmes in this NSCLC patient population to date.

* BIBF 1120 is an investigational compound. Its safety and efficacy have not yet been fully established.
VIEW PREVIEW ADD TO SELECTION DOWNLOAD